Description: <h3>Centella asiatica / Gotu kola → Asiaticoside</h3>
<p>
<strong>Centella asiatica</strong>, commonly known as <strong>Gotu kola</strong>,
is a medicinal botanical used mainly for wound healing, skin repair,
microcirculation support, anti-inflammatory effects, and possible
neuroprotective activity.
</p>
<ul>
<li><strong>Primary database product:</strong> Centella asiatica standardized extract</li>
<li><strong>Common name / alias:</strong> Gotu kola</li>
<li><strong>Other aliases:</strong> Indian pennywort, tiger grass, cica</li>
<li><strong>Best form:</strong> Standardized Centella asiatica extract / titrated triterpenes</li>
<li><strong>Main active marker:</strong> Asiaticoside</li>
<li><strong>Other key actives:</strong> Madecassoside, asiatic acid, madecassic acid</li>
<li><strong>Compound class:</strong> Pentacyclic triterpenoid saponins / triterpenes</li>
</ul>
<p>
<strong>Asiaticoside</strong> is one of the major active and marker compounds
in Centella asiatica.
</p>
<ul>
<li><strong>Asiaticoside role:</strong> Active constituent / quality marker</li>
<li><strong>Source:</strong> Centella asiatica / Gotu kola</li>
<li><strong>Main activities:</strong> Wound repair, collagen synthesis, fibroblast support, anti-inflammatory, antioxidant, skin barrier support</li>
<li><strong>Relevant pathways:</strong> TGF-β/collagen, VEGF/angiogenesis, NF-κB, IL-1β, IL-6, TNF-α, COX-2/PGE2, oxidative stress pathways</li>
</ul>
<p>
<strong>Structure:</strong>
</p>
<pre>
Centella asiatica / Gotu kola
→ Asiaticoside
→ Madecassoside
→ Asiatic acid
→ Madecassic acid
</pre>
<p><b>Centella asiatica / Gotu kola → asiaticoside</b> — Centella asiatica is a medicinal botanical extract source, and asiaticoside is one of its major pentacyclic triterpenoid saponin marker constituents. The formal classification is botanical standardized extract / natural-product triterpenoid saponin modality, not an approved anticancer drug. The principal active family includes asiaticoside, madecassoside, asiatic acid, and madecassic acid; asiaticoside can also be metabolically linked to asiatic acid. Asiaticoside as the main active marker, with Centella asiatica standardized extract as the primary product.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>NF-κB and inflammatory cytokine suppression, especially reduced TNF-α, IL-1β, IL-6, COX-2/PGE2, and downstream survival signaling in inflammatory and tumor models.</li>
<li>Mitochondrial apoptosis induction in cancer cells, with Bax:Bcl-2 shift, MMP loss, caspase-9 activation, caspase-3 activation, and p53/p21-associated cell-cycle arrest reported in preclinical models.</li>
<li>Anti-migration and anti-EMT effects, including suppression of p65/NF-κB-linked EMT, YAP1/VEGFA signaling, invasion, and radiation-induced migration in selected cancer-cell systems.</li>
<li>PI3K/Akt/mTOR/STAT3 modulation, more strongly supported for asiatic acid than for asiaticoside itself, with relevance to proliferation, survival, autophagy, and metastatic phenotype.</li>
<li>TGF-β/collagen/fibroblast and wound-repair axis activation in normal tissue contexts; beneficial for repair but mechanistically ambiguous in cancer because fibrosis and angiogenesis can be tumor-context dependent.</li>
<li>Oxidative-stress modulation, generally antioxidant and cytoprotective in normal cells; ROS/NRF2 effects are secondary and context-dependent rather than the core anticancer mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral translation is constrained by variable extract composition, limited dissolution and bioavailability of triterpenes, metabolism of glycosides to aglycones, and formulation dependence. Standardized extracts such as ECa 233 and aqueous Centella asiatica products have human phase-1 PK data, but systemic exposure is still not equivalent to common high-concentration in-vitro cancer experiments.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Cancer-cell studies commonly use micromolar asiaticoside or asiatic-acid exposures that may exceed or not cleanly map onto achievable plasma exposure after oral botanical dosing. Topical and local tissue uses are more plausible for skin/wound biology than systemic anticancer effects. For cancer translation, the entry should be treated as concentration- and formulation-dependent.</p>
<p><b>Clinical evidence status:</b> Cancer relevance is weak / preclinical only, with no established oncology indication. Human evidence is stronger for wound healing, venous/skin-related uses, and early cognitive/AD-oriented safety or PK studies than for cancer treatment. AD relevance is possible / early clinical, with phase-1 target-engagement work in mild cognitive impairment or mild Alzheimer’s disease, but no proven disease-modifying efficacy.</p>
<h3>Centella asiatica and Asiaticoside Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NF-κB inflammatory survival axis</td>
<td>NF-κB↓, p65↓, TNF-α↓, IL-1β↓</td>
<td>NF-κB↓, inflammatory cytokines↓</td>
<td>R,G</td>
<td>Anti-inflammatory and anti-survival signaling</td>
<td>Most central cross-context mechanism; supports anticancer, neuroinflammatory, and wound-healing interpretations but is not cancer-specific.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>MMP↓, Bax:Bcl-2↑, caspase-9↑, caspase-3↑</td>
<td>Apoptosis↔ or ↓ in injury models (context-dependent)</td>
<td>G</td>
<td>Intrinsic apoptotic priming in tumor models</td>
<td>Preclinical cancer-cell effect; selectivity depends strongly on dose, cell line, and compound form.</td>
</tr>
<tr>
<td>3</td>
<td>Cell-cycle checkpoint and p53 axis</td>
<td>p53↑, p21↑, cyclin D1↓, CDK4↓</td>
<td>Cell-cycle stress↔ (context-dependent)</td>
<td>G</td>
<td>Growth arrest and reduced proliferation</td>
<td>cytostatic activity; best treated as model-dependent rather than universal.</td>
</tr>
<tr>
<td>4</td>
<td>EMT migration invasion axis</td>
<td>Migration↓, invasion↓, EMT↓, YAP1/VEGFA↓, p65↓</td>
<td>Repair migration↑ in wound contexts (context-dependent)</td>
<td>G</td>
<td>Reduced metastatic phenotype in selected models</td>
<td>Important because Centella can promote normal wound repair while suppressing tumor-cell invasion in some systems; interpretation is tissue-context dependent.</td>
</tr>
<tr>
<td>5</td>
<td>PI3K Akt mTOR STAT3 survival axis</td>
<td>PI3K/Akt↓, mTOR↓, STAT3↓ (mainly asiatic acid)</td>
<td>Mixed cytoprotection or survival signaling↔</td>
<td>R,G</td>
<td>Reduced survival, proliferation, and metastatic signaling</td>
<td>Better supported for asiatic acid than asiaticoside; include as related triterpene-family mechanism rather than asiaticoside-only claim.</td>
</tr>
<tr>
<td>6</td>
<td>Autophagy axis</td>
<td>LC3-II↑, autophagy↑ (model-dependent)</td>
<td>Autophagy↔ or ↑ (context-dependent)</td>
<td>G</td>
<td>Stress adaptation or autophagic cell death</td>
<td>Direction and therapeutic meaning are model-dependent; can be pro-death or protective depending on tumor context.</td>
</tr>
<tr>
<td>7</td>
<td>ROS antioxidant NRF2 stress axis</td>
<td>ROS↔ or ↑ during apoptosis (context-dependent)</td>
<td>Oxidative stress↓, antioxidant defense↑, NRF2↔ or ↑</td>
<td>R,G</td>
<td>Normal-cell protection and redox modulation</td>
<td>Secondary mechanism. </td>
</tr>
<tr>
<td>8</td>
<td>TGF-β collagen fibroblast repair axis</td>
<td>TGF-β effects↔ (context-dependent)</td>
<td>Collagen synthesis↑, fibroblast activity↑, wound repair↑</td>
<td>G</td>
<td>Tissue repair and matrix remodeling</td>
<td>Core for Centella’s non-cancer use; potentially undesirable in some tumor-stroma or fibrosis contexts.</td>
</tr>
<tr>
<td>9</td>
<td>VEGF angiogenesis axis</td>
<td>VEGFA↓ in some breast cancer models</td>
<td>Angiogenesis↑ during wound repair (context-dependent)</td>
<td>G</td>
<td>Opposite effects depending on cancer versus repair context</td>
<td>Important interpretive caution: normal repair biology and cancer biology may diverge.</td>
</tr>
<tr>
<td>10</td>
<td>Radiosensitization migration constraint</td>
<td>Radiation-induced migration↓, invasion↓</td>
<td>Radioprotection↔ unknown</td>
<td>G</td>
<td>Anti-invasive adjunct signal after irradiation</td>
<td>Evidence is preclinical and more anti-migration than classic radiosensitization</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>High in-vitro exposure required (often)</td>
<td>Rare hepatotoxicity risk; product variability</td>
<td>G</td>
<td>Limits systemic anticancer translation</td>
<td>Bioavailability, formulation, extract standardization, dose limitation, and weak oncology trial evidence are the main constraints.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br><br>
<p>
<strong>AD relevance:</strong> Possible / preclinical. Interest is mainly through
neuroinflammation, oxidative stress, mitochondrial protection, and general
neuroprotective mechanisms.
</p>
<p><b>Alzheimer’s disease relevance:</b> Centella asiatica / Gotu kola has a plausible but unproven AD-oriented profile. The strongest rationale is not direct amyloid clearance as an established clinical effect, but combined modulation of neuroinflammation, oxidative stress, mitochondrial metabolism, synaptic or neuronal viability markers, and vascular/microcirculatory support. Human evidence is early: phase-1 PK/safety and target-engagement studies exist in older adults with mild cognitive impairment or mild Alzheimer’s disease, but efficacy remains unproven.</p>
<p><b>Clinical evidence status:</b> AD / cognition evidence is preclinical plus small human and phase-1 clinical work. Early translational / investigational rather than established therapy.</p>
<p>
<strong>Cancer relevance:</strong> Weak / preclinical.
</p>
<h3>AD-Oriented Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neuroinflammation NF-κB cytokine axis</td>
<td>NF-κB↓, TNF-α↓, IL-1β↓</td>
<td>Reduced inflammatory signaling</td>
<td>Most defensible AD-relevant mechanism; not disease-specific.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial metabolism neuronal viability</td>
<td>Mitochondrial function↑, metabolic stress↓</td>
<td>Neuronal bioenergetic support</td>
<td>Central to current target-engagement rationale in cognitive impairment studies.</td>
</tr>
<tr>
<td>3</td>
<td>Oxidative stress DNA oxidation axis</td>
<td>Oxidative stress↓, 8OHdG↓ (candidate marker)</td>
<td>Reduced oxidative injury</td>
<td>Relevant to trial biomarker strategy; clinical disease modification unproven.</td>
</tr>
<tr>
<td>4</td>
<td>Synaptic memory and neuronal morphology axis</td>
<td>Learning and memory markers↑ (model-dependent)</td>
<td>Cognitive-support signal in animals</td>
<td>Preclinical support is stronger than human efficacy evidence.</td>
</tr>
<tr>
<td>5</td>
<td>Amyloid-associated pathology</td>
<td>β-amyloid stress↓ (model-dependent)</td>
<td>Reduced amyloid-model metabolic disturbance</td>
<td>model-dependent, not as proven anti-amyloid clinical activity.</td>
</tr>
<tr>
<td>6</td>
<td>Clinical Translation Constraint</td>
<td>Bioavailability↔, extract variability↑, evidence limitation↑</td>
<td>Limits AD clinical interpretation</td>
<td>Current status is investigational; formulation, heavy-metal quality, dose, and trial endpoints matter.</td>
</tr>
</tbody>
</table>